Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Latest from Memorial Sloan Kettering Cancer Center

Tremelimumab Plus Durvalumab Improves Survival in Frontline Unresectable HCC

October 15, 2021

A single, high priming dose of tremelimumab plus durvalumab resulted in a statistically significant and clinically meaningful improvement in overall survival vs sorafenib when used in the frontline treatment of patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy and were not eligible for localized treatment.

Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial

October 14, 2021

The initiation of the phase 3 ENHANCE trial looks to build on the generally early response to azacitidine with the addition of magrolimab, a first-in-class monoclonal antibody, for patients with intermediate-, high-, and very high–risk myelodysplastic syndrome.

Pivotal MagnetisMM-3 Trial Aims to Add Elranatamab in Multiple Myeloma Treatment

September 27, 2021

Patients with relapsed/refractory multiple myeloma, particularly those who have failed a prior BCMA–targeted therapy, represent a population with an unmet need for effective treatment options. Investigators are hoping to help fill this void with the initiation of the phase 2 MagnetisMM-3 study.

U2 Plus Pembrolizumab Shows Continued Efficacy at 5 Years in CLL and Richter’s Transformation

September 20, 2021

The triplet combination of umbralisib, ublituximab, and pembrolizumab demonstrated durable responses with a tolerable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia and Richter’s transformation.

Nivolumab/Chemo Combo Sustains Clinical Benefit in Frontline Gastric/GEJ Cancer, But Nivolumab/Ipilimumab Arm Misses Mark

September 19, 2021

The frontline combination of nivolumab and chemotherapy upheld its improvement in progression-free and overall survival vs chemotherapy alone with longer follow-up of patients with advanced gastric, gastroesophageal junction, or esophageal cancer, according to data from the phase 3 CheckMate-649 trial.

Initial Guideline Development Showcases Future Directions in Ultra-Rare Sarcoma Subtype

September 15, 2021

As part of a global consensus meeting, experts from several disciplines convened to define evidence-based guidelines for the treatment of patients with primary and metastatic epithelioid hemangioendothelioma with locoregional and systemic therapies, as well as palliative care.

Pembrolizumab Plus Lenvatinib Improves Survival in dMMR Endometrial Cancer

September 07, 2021

The combination of pembrolizumab and lenvatinib led to a statistically significant improvement in progression-free survival and overall survival in patients with mismatch repair deficient advanced endometrial cancer following platinum-based chemotherapy.

Emerging Options Open the Door to Optimized Treatment Opportunities in Hematologic Malignancies

September 01, 2021

More tailored selection processes, which have placed a greater emphasis on patient-specific characteristics, such as risk and genomic status, and made possible with a growing number of treatment options, have led to optimized therapeutic decisions for patients with hematologic malignancies.

P-PSMA-101 Elicits Encouraging Responses in Metastatic Castration-Resistant Prostate Cancer

September 01, 2021

The autologous CAR T-cell therapy P-PSMA-101 elicited robust antitumor responses in patients with metastatic castration-resistant prostate cancer, according to preliminary findings from the phase 1 P-PSMA-101-001 trial that were virtually presented during the 6th Annual CAR-TCR Summit.